Kura Oncology (NASDAQ:KURA) Hits New 52-Week Low – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $8.76 and last traded at $8.94, with a volume of 1384631 shares. The stock had previously closed at $9.01.

Wall Street Analysts Forecast Growth

KURA has been the topic of several research analyst reports. HC Wainwright lifted their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, UBS Group initiated coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.86.

Kura Oncology Stock Performance

The firm has a fifty day moving average price of $13.92 and a 200 day moving average price of $17.93. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently bought and sold shares of KURA. nVerses Capital LLC purchased a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $25,000. Point72 DIFC Ltd purchased a new position in Kura Oncology in the third quarter worth approximately $146,000. Quarry LP acquired a new stake in Kura Oncology during the second quarter worth $196,000. Erste Asset Management GmbH acquired a new stake in Kura Oncology during the third quarter worth $215,000. Finally, Bellevue Group AG raised its position in Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.